Cowen & Co. Reaffirms Their Buy Rating on Allogene Therapeutics Inc (ALLO)

By Jason Carr

In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Allogene Therapeutics Inc (ALLOResearch Report). The company’s shares opened today at $28.38.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 7.8% and a 48.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.

Allogene Therapeutics Inc has an analyst consensus of Moderate Buy.

See today’s analyst top recommended stocks >>

The company has a one-year high of $35.55 and a one-year low of $21.67. Currently, Allogene Therapeutics Inc has an average volume of 426.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. It also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, other blood cancers and solid tumors.